Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Hypertens. 2013 Feb;31(2):321–332. doi: 10.1097/HJH.0b013e32835b50aa

TABLE 1. Data from metabolic cages studies.

Group name UNOxV (μmol/day) IISOV (ng/day) UTBARSV (μmol/day) UH2O2V (μmol/day)
I3C-induced + untreated 19.68 ± 1.44# 21.74 ± 2.45 0.24 ± 0.06 0.46 ± 0.09
I3C-induced + c-AUCB 9.88 ± 0.91* 19.86 ± 1.74 0.32 ± 0.07 0.37 ± 0.07
I3C-induced + L-NAME 4.09 ± 0.99 21.72 ± 1.24 0.27 ± 0.05 0.41 ± 0.05
I3C-induced + L-NAME + c-AUCB 4.14 ± 0.56 22.14 ± 1.96 0.25 ± 0.04 0.43 ± 0.05
I3C-induced + L-NAME + RAS blockade 3.89 ± 1.01 20.72 ± 2.71 0.31 ± 0.06 0.39 ± 0.07
Noninduced + untreated 11.98 ± 0.91* 25.14 ± 2.02 0.27 ± 0.04 0.43 ± 0.06
Noninduced + c-AUCB 10.42 ± 0.96* 20.81 ± 1.96 0.32 ± 0.06 0.47 ± 0.09
Noninduced + L-NAME 4.12 ± 0.56 22.42 ± 1.76 0.29 ± 0.05 0.38 ± 0.06
Noninduced + L-NAME + c-AUCB 4.86 ± 0.64 19.86 ± 2.64 0.31 ± 0.06 0.42 ± 0.06
Noninduced + L-NAME + RAS blockade 5.04 ± 0.86 25.17 ± 2.89 0.28 ± 0.07 0.43 ± 0.07

c-AUCB, treatment with the soluble epoxide hydrolase inhibitor; I3C, administration of indole-3-carbinol; IISOV, urinary 8-isoprostane excretion; L-NAME, treatment with nitric oxide synthase inhibitor; RAS, renin–angiotensin system; UH2O2V, urinary hydrogen peroxide excretion; UNOxV, urinary nitrate/nitrite excretion; UTBARSV, urinary thiobarbituric acid-reactive substances excretion.

*

P < 0.05 vs. unmarked values.

#

P < 0.05 vs. all values.